| Name | Title | Contact Details |
|---|
VFO LLC provides accounting and finance services to early stage start-up companies in any industry. From day-to-day bookkeeping activity to financial forecasts.
Joshu is an insurance product development and distribution platform that helps insurance product owners configure, launch and update their products without coding. Designed for insurance professionals and packed with features accelerating product setup, Joshus portals and Underwriter Desk come out of the box and support the full lifecycle of a policy. Founded by technology experts experienced in selling insurance online, Joshu was purpose-built to give insurance professionals the tools they need to harness digital distribution and win new markets faster.
Autonomous Solutions, Inc. (ASI) is a leader in industrial vehicle automation, focusing on retrofitting existing equipment with autonomous technology. Founded in 2000 and based in Petersboro, Utah, ASI operates a 100-acre proving ground for robotics testing. The company provides OEM/vendor-independent automation solutions for various sectors, employing between 201 and 500 staff and serving clients across six continents. ASI offers a range of products and services, including the Mobius® Fleet Management System for coordinating autonomous fleets and custom automation kits for vehicles of all sizes. Their solutions cater to multiple industries, such as mining, automotive, agriculture, military, construction, logistics, security, and research. Notable clients include Ford Motor Company, Anglo American, John Deere, and the U.S. Department of Defense. ASI emphasizes all-weather, 24/7 operation, enhancing efficiency and reducing costs in applications like landscaping.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.